Large gap with delayed quotes
|
Last quote
12/26/2024 -
20:00:00
|
Bid
12/27/2024 -
07:00:13
|
Bid Volume |
Ask
12/27/2024 -
07:00:13
|
Ask Volume |
|---|---|---|---|---|
|
140.31
+1.52
(
+1.10% )
|
115.66
|
100 |
173.68
|
100 |
Analysis date: 24.12.2024
Global Evaluation
Slightly positive
Slightly positive
The stock is classified in the slightly positive zone since 17.12.2024.
Interest
Weak
Weak
Weak interest since 13.12.2024.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 15.11.2024 at a price of 126.51.
Evaluation
Overvalued
Overvalued
Based on its growth potential and our own criteria, at its current price the stock is moderately overvalued.
MT Tech Trend
Positive
Positive
The forty day Medium Term Technical Trend is positive since 26.11.2024. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 130.948.
4wk Rel Perf
5.19%
5.19%
The four week relative overperformance versus SP500 is 5.19%.
Sensibility
Low
Low
The stock has been on the low-sensitivity level since 01.10.2024.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.71%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.24%.
Mkt Cap in $bn
8.35
8.35
With a market capitalization >$8bn, ASCENDIS PHARMA is considered a large-cap stock.
G/PE Ratio
0.67
0.67
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
232.64
232.64
The estimated PE is for the year 2026.
LT Growth
156.88%
156.88%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
11
11
Over the last seven weeks, an average of 11 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
72
72
For 1% of index variation, the stock varies on average by 0.72%.
Correlation
0.20
0.20
Stock movements are strongly independent of index variations.
Value at Risk
16.65
16.65
The value at risk is estimated at USD 16.65. The risk is therefore 12.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
17.04.2018
17.04.2018